Treatment interruption for convenience, cost cutting and toxicity sparing

Current Opinion in HIV and AIDS

Volumn 2, Issue 1, 2007, Pages 31-38

  Nüesch, Reto ^a   Hirschel, Bernhard ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Antiretroviral therapy; Efficacy; Interruption; Quality of life; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

ASTHENIA; CD4 LYMPHOCYTE COUNT; COST MINIMIZATION ANALYSIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EXPOSURE; DRUG SUBSTITUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIPODYSTROPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; RISK; SIDE EFFECT; TREATMENT FAILURE; TREATMENT INTERRUPTION; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS LOAD;

EID: 34250647036     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328011a1df     Document Type: Review

References (66)

1. Duncombe C, Kerr SJ, Ruxrungtham K, et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS 2005; 19:169-178.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
5. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38:174-179.
6. Benson CA. Structured treatment interruption in HIV infection. AIDS Reader 2001; 11:99-102.
7. Lori F, Maserati R, Foli A, et al. Structured treatment interruptions to control HIV-1 infection. Lancet 2000; 355:287-288.
8. Hirschel B. Planned interruptions of anti-HIV treatment. Lancet Infect Dis 2001; 1:53-59.
9. Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 2000; 23:236-245.
10. Colette JS, Sabin CA, Lampe FC, et al. The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens. Antivir Ther 2005; 10:459-467.
11. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-1327.
12. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
13. Silverberg MJ, Gore ME, French AL, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 2004; 39:717-724.
14. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
15. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-192.
16. Nuesch R, Srasuebkul P, Ananworanich J, et al. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother 2006; 58:637-644. A Thai cohort showing that grade III-IV laboratory toxicity is frequent but can be detected with very few tests.
17. Brown P. Cheaper AIDS drugs due for third world. Nature 2000; 405:263.
18. Cohen J. AIDS treatment: a step toward cheaper anti-HIV therapy. Science 2005; 307:653.
19. Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536. A comprehensive review on many aspects of expanding HIV therapy worldwide.
20. Piot P, Feachem RG, Lee JW, Wolfensohn JD. Public health: a global response to AIDS - lessons learned, next steps. Science 2004; 304: 1909-1910.
21. Schwartlander B, Grubb I, Perriens J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet 2006; 368:541-546. A description of what has been done so far to provide worldwide coverage of ART.
22. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-728.
23. Strain MC, Gunthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 2003; 100:4819-4824.
24. van Rij RP, van Praag RM, Prins JM, et al. Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. Antivir Ther 2002; 7:37-41.
25. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 1999; 96:10958-10961.
26. Taffe P, Rickenbach M, Hirschel B, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. AIDS 2002; 16:747-755.
27. Touloumi G, Pantazis N, Antoniou A, et al. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 2006; 42:554-561.
28. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-1684.
29. Alexander TH, Ortiz GM, Wellons MF, et al. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr 2003; 34:475-481.
30. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A 2001; 98:15161-15166.
31. Fischer M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds within days during structured treatment interruptions. AIDS 2003; 17:195-199.
32. Garcia F, Plana M, Arnedo M, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003; 17:43-51.
33. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79-F86.
34. Lori F, Foli A, Maserati R, et al. Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clin Trials 2002; 3:115-124.
35. Hance AJ, Lemiale V, Izopet J, et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing anti-retroviral therapy. J Virol 2001; 75:6410-6417.
36. Ruiz L, Carcelain G, Martinez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F19-F27.
37. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000; 14:1935-1942.
38. Tuldra A, Fumaz CR, Ferrer MJ, et al. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS 2001; 15:1904-1906.
39. Marchou P, Tangre I, Charreau J, et al. Structured treatment interruptions in HIV-infected patients with high CD4 cell counts and virologic suppression: results of a prospective, randomized open-label trial (Window-ANRS 106). In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA. 5-8 February 2006, Abstract 104.
40. Papasavvas E, Kostman JR, Mounzer K, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:e64.
41. Giuliano M, Palmisano L, Bucciardini R, et al. and the Italian ISS-PART Clinical Centers. Factors predicting success and resistance in the STI arm of a randomized, controlled trial of continuous versus intermittent HAART. In: XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006. Abstract THPE0146.
42. Maserati R, Tomasoni L, Di Pietro M, et al. Structured treatment interruptions in chronically infected HIV+ patients with long lasting suppressed viremia: metabolic, anthropometric and quality of life outcomes from a prospective, randomized, controlled trial. In: 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13 July 2003. Abstract 604.
43. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. A large and well designed randomized controlled trial on CD4 cell count-guided treatment interruption performed exclusively in Africa.
44. Hakim J, on behalf of the DART Trial Team. A structured treatment interruption strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial. In: XVIth International AIDS Conference. Toronto, Canada, 13-18 August 2006. Abstract THLB0207.
45. Cohen C, Colson A, Morris A, et al. The FOTO Study 48 week results: viral suppression can be maintained when antiretrovirals are taken five consecutive days on, and two days off each week. In: 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005. Abstract WePe12.4C10.
46. Ruiz L, Paredes R, Gómez G, et al. Antiretroviral therapy interruption guided by CD4 T-cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2006; 20 (in press).
47. Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr 2005; 39:523-529. A pilot study to the larger Staccato trial. The CD4 cell count-guided arm was safe despite the fact that patients had had previous dual nucleoside therapy.
48. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465. A well designed multinational randomized controlled trial showing equal efficacy of CD4 cell count-guided STI on virological response and new AIDS.
49. El Sadr W, Neaton J, for the SMART Study Investigators. Episodic CD4-guided use of antiretroviral therapy is inferior to continuous therapy: results of the SMART study. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO. 5-8 February 2006. Abstract 106 LB.
50. Burman W, for the SMART Study Group. The effect of episodic CD4-guided antiretroviral therapy on quality of life: results of the quality of life substudy of SMART. In: XVIth International AIDS Conference, Toronto, Canada. 13-18 August 2006. Abstract THPE0145.
51. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
52. Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005; 40:594-600. A randomized controlled trial showing the failure of the week on/off strategy. The trial was a pilot to Staccato and patients included had had previous dual nucleoside therapy.
53. Maggiolo F, Ripamonti D, Gregis G, et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
54. Negredo E, Rodriguez-Santiago B, Puig J, et al. Effect of prolonged interruption of ART on mitochondrial toxicity. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006. Abstract 758.
55. Martinez-Lopez E, Negredo E, Miranda C, et al. Impact of antiretroviral treatment interruption on morphologic changes: the Tibet Substudy. In: 3rd IAS Conference on HIV Pathogenesis and Treatment. Bangkok, Thailand, 11-16 July 2004. Abstract TuPe2.4C17.
56. Nuesch R, Ananworanich J, Sirivichayakul S, et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005; 40:728-734. This investigation on genotypic resistance showed that resistance was not induced through CD4 cell count-guided interruption.
57. Nüesch R. The Trivacan study. Lancet 2006; 368:915-916.
58. Hogg RS, Weber AE, Craib KJ, et al. One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS 1998; 12:2203-2209.
59. Yazdanpanah Y. Costs associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 558-561.
60. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824. A merger of various cohort studies in industrialized and low-income countries.
61. Goldie S, Yazdanpahah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings: the case of Côte d'Ivoire. N Engl J Med 2006; 355:1141-1153. A thorough cost-effectiveness analysis of ART in settings with limited resources.
62. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776.
63. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-2226.
64. Teicher E, Casagrande T, Vittecoq D. Enhanced risk of HIV sexual transmission during structured treatment interruption. Sex Transm Infect 2003; 79:74.
65. Wolf K, Young J, Rickenbach M, et al. Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2003; 33:494-499.
66. McClelland RS, Baeten JM, Richardson BA, et al. A comparison of genital HIV-1 shedding and sexual risk behaviour among Kenyan women based on eligibility for initiation of HAART according to WHO guidelines. J Acquir Immune Defic Syndr 2006; 41:611-615.